肝胆胰（HBP）癌症患者治疗前血清铁蛋白水平的预后价值的 Meta 分析。
Meta-analysis of the prognostic value of pretreatment serum ferritin in hepatobiliary and pancreas (HBP) cancers.
机构信息
General Surgery, Binhaiwan Central Hospital of Dongguan, Dongguan, China.
Pain, Binhaiwan Central Hospital of Dongguan, Dongguan, China.
出版信息
BMJ Open. 2021 May 28;11(5):e040801. doi: 10.1136/bmjopen-2020-040801.
BACKGROUND AND OBJECTIVES
Studies have shown that serum ferritin (SF) has unfavourable prognostic value in hepatobiliary and pancreas (HBP) cancers. This meta-analysis aimed to comprehensively assess the prognostic role of pretreatment SF in patients with HBP cancers.
METHODS
Eligible studies published before January 2020 were obtained through a comprehensive search in the PubMed, Web of Science, Cochrane Library and EMBASE databases. Pooled HRs and 95% CIs were then employed as effect sizes.
RESULTS
Seven studies comprising 1244 patients were pooled. Elevated pretreatment SF was associated with worse overall survival (OS) (HR 1.60, 95% CI 1.36 to 1.88, p<0.001) and recurrence-free survival/progression-free survival/time to recurrence (HR 1.70, 95% CI 1.15 to 2.52, p=0.008). Significant prognostic value of elevated pretreatment SF on OS was detected in the subgroups regardless of the cancer type, race, SF cut-off value, tumour-node-metastasis stage and Newcastle-Ottawa Scale score.
CONCLUSION
Elevated pretreatment SF was associated with worse survival outcome of patients with HBP cancers. As such, it may serve as a novel prognostic biomarker for HBP cancers.
背景和目的
研究表明，血清铁蛋白（SF）在肝胆胰（HBP）癌症中具有不良的预后价值。本荟萃分析旨在全面评估 HBP 癌症患者治疗前 SF 的预后作用。
方法
通过在 PubMed、Web of Science、Cochrane Library 和 EMBASE 数据库中进行全面检索，获取到 2020 年 1 月之前发表的符合条件的研究。然后采用合并 HR 和 95%CI 作为效应量。
结果
纳入了 7 项研究，共 1244 名患者。升高的治疗前 SF 与较差的总生存期（OS）（HR 1.60，95%CI 1.36 至 1.88，p<0.001）和无复发生存率/无进展生存率/复发时间（HR 1.70，95%CI 1.15 至 2.52，p=0.008）相关。无论癌症类型、种族、SF 截断值、肿瘤-淋巴结-转移分期和纽卡斯尔-渥太华量表评分如何，升高的治疗前 SF 在 OS 的亚组中均具有显著的预后价值。
结论
升高的治疗前 SF 与 HBP 癌症患者的生存结局较差相关。因此，它可能作为 HBP 癌症的一种新的预后生物标志物。
Zotero 插件